B-cell leukemia

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

Retrieved on: 
Monday, April 8, 2024
Sarah Cannon Research Institute, B-cell leukemia, AML, B-ALL, Patient, Webcast, Neoplasm, Acute myeloid leukemia, Cancer, Syndrome, Spacecraft, Camptothecin, AACR, DLT, PALO, Antibody, Drug development, Safety, Infrared spectroscopy correlation table, MDS, Therapy, ADC, Drug resistance, Pharmaceutical industry

PALO ALTO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • We are still in dose escalation and are starting to see tumor reduction after only two doses.
  • The study's main objective is to determine a safe dose and schedule for VIP236 for further clinical development.
  • As the study progresses through the dose escalation, Vincerx will present additional Phase 1 data for VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
  • An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 January 2024

Retrieved on: 
Saturday, January 13, 2024
B cell, Risk management, Association, Data, Patient, Leukemia, European, Signal, Database, Brexucabtagene autoleucel, DSM-IV codes, Father, B-cell lymphoma, Follicular lymphoma, State, Mantle cell lymphoma, Male, RMP, Migraine, Civil service commission, European Commission, Birth, Medicine, Cancer, EMA, Risk, Public, Communication, Bipolar disorder, Pregnancy, T-cell lymphoma, Multiple myeloma, Epilepsy, COVID-19, Child, PRAC, Bone marrow, Neurodevelopmental disorder, Marketing, B-cell leukemia, Vaccine, Review, Man

EMA’s safety committee (PRAC) is recommending precautionary measures for the treatment of male patients with valproate medicines.

Key Points: 
  • EMA’s safety committee (PRAC) is recommending precautionary measures for the treatment of male patients with valproate medicines.
  • A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association between a medicine…, Ongoing referralsProcedureStatusUpdateHydroxyprogesterone-containing medicinal products – Article-31 referralUnder evaluationPRAC continued its assessment

Communities Across the U.S. to Join Olympians at Legendary Deer Valley Resort to End Blood Cancer

Retrieved on: 
Monday, November 6, 2023
ET, Policy, Education, Leukemia, Snow, B-cell leukemia, RYE, Research, Volunteering, Nausea, Dare, Red, LLS, Pedal, Leg, Clinical trial, Packed red blood cells, Leukemia & Lymphoma Society, Bone marrow, One and a Half Summer, Cancer, Acute leukemia, Skiing, Investment, Patient, Back pain, Tumors of the hematopoietic and lymphoid tissues, Nursing care plan, Pharmaceutical industry, Birth control

RYE BROOK, N.Y., Nov. 6, 2023 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is kicking off the ski season with huge goal in mind: to end blood cancer. Communities nationwide will be joined by past Olympians including Nordic skier Bryan Fletcher at LLS's "Shred For Red" event at the legendary Deer Valley Resort in Park City, UT, often referred to as "The Greatest Snow on Earth".

Key Points: 
  • Communities nationwide will be joined by past Olympians including Nordic skier Bryan Fletcher at LLS's " Shred For Red " event at the legendary Deer Valley Resort in Park City, UT, often referred to as "The Greatest Snow on Earth".
  • Happening on December 2, Shred For Red is a fun and family-friendly event where dedicated volunteers raise funds to end blood cancer, while skiing some of the best slopes in the world and enjoying lively winter activities.
  • With a more than 70-year track record, LLS has supported virtually every advancement in blood cancer treatment.
  • Blood cancer patients and their families can contact the LLS Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas

Retrieved on: 
Wednesday, March 8, 2023
UTPD, IND, Acquisition, CRS, Cytokine release syndrome, NHL, Investigational New Drug, UC Davis Health Stadium, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurotoxicity, Patient, Cancer, HIV, Food, Immune system, Lymphoma, CNS, FDA, CD19, B-cell leukemia, Safety, UC, Pharmaceutical industry

EMERYVILLE, Calif. and NEW YORK, March 8, 2023 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer with safe, effective therapies, and TradeUP Acquisition Corp. ("TradeUP") (NASDAQ: UTPD), a special purpose acquisition company formed for the purpose of effecting a merger, acquisition or similar business combination, today announced that the U.S. Food and Drug Administration ("FDA") has cleared Estrella's Investigational New Drug ("IND") application for Estrella's lead product candidate, EB103, a T-cell therapy targeting CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas, paving the way for Estrella to initiate a Phase I/II clinical trial of EB103 to treat relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) patients, including clearance to treat patients with some of the highest unmet medical needs, including those with human immunodeficiency virus (HIV)-associated lymphoma, and primary and secondary central nervous system (CNS) lymphoma.

Key Points: 
  • "Our goal is to develop a safe and effective therapy that can help address the unmet medical needs of patients with R/R B-cell malignancies, including those who are currently underserved by existing therapies.
  • We hope to enroll our first patient in the second half of 2023."
  • The Starlight-1 Phase I/II clinical trial is designed to assess the safety, tolerability, recommended Phase II dose (RP2D), and preliminary anti-cancer activity of EB103 for the treatment of R/R B-cell NHL patients.
  • The study is expected to enroll patients initially at UC Davis Health.

Acute Lymphoblastic Leukemia Market is Expected to Grow with 4.8% CAGR During the Study Period of 2017-30 in 7 Major Markets

Retrieved on: 
Thursday, June 25, 2020
RTT, Acute lymphocytic leukemia, Cancer, Leukemia, Lymphoblast, Acute lymphoblastic leukemia, Branches of biology, Acute leukemia, B-cell leukemia

CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."

Key Points: 
  • CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."
  • LAS VEGAS, June 25, 2020 /PRNewswire/ -- DelveInsight has announced the expansion of the forecast period to 2020-2030 for its report on ' Acute Lymphoblastic Leukemia (ALL) Market Insight, Epidemiology and Market Forecast -2030' .
  • B-cell lymphoblastic leukemia accounted for the majority of cases, i.e., 82% of total ALL cases, in comparison of T-cell lymphoblastic leukemia.
  • The United States accounted for the highest Acute lymphoblastic leukemia market size, followed by Germany and France among the 7MM countries.

Acute Lymphoblastic Leukemia Market is Expected to Grow with 4.8% CAGR During the Study Period of 2017-30 in 7 Major Markets

Retrieved on: 
Thursday, June 25, 2020
RTT, Acute lymphocytic leukemia, Cancer, Leukemia, Lymphoblast, Acute lymphoblastic leukemia, Branches of biology, Acute leukemia, B-cell leukemia

CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."

Key Points: 
  • CAR-T cell therapies are expected to dominate the Acute lymphoblastic leukemia market as five of the immunotherapies in the pipeline are geared up to enter the market by 2023."
  • LAS VEGAS, June 25, 2020 /PRNewswire/ -- DelveInsight has announced the expansion of the forecast period to 2020-2030 for its report on ' Acute Lymphoblastic Leukemia (ALL) Market Insight, Epidemiology and Market Forecast -2030' .
  • B-cell lymphoblastic leukemia accounted for the majority of cases, i.e., 82% of total ALL cases, in comparison of T-cell lymphoblastic leukemia.
  • The United States accounted for the highest Acute lymphoblastic leukemia market size, followed by Germany and France among the 7MM countries.

B-Cell Chronic Lymphocytic Leukemia Pipeline Insight, 2019 Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2019
Health, Oncology, Pharmaceutical, RTT, Cancer, Leukemia, Lymphoid leukemia, Chronic lymphocytic leukemia, Lymphocytic leukemia, Clinical medicine, Prolymphocytic leukemia, B-cell leukemia

The "B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across B-Cell Chronic Lymphocytic Leukemia development.
  • The report assesses the active B-Cell Chronic Lymphocytic Leukemia pipeline products by developmental stage, product type, molecule type, and administration route.
  • clinical, pre-clinical and discovery stages for the B-Cell Chronic Lymphocytic Leukemia
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for B-Cell Chronic Lymphocytic Leukemia

Lymphocytic Leukemia Pipeline Market (ALL) 2018 Analysis, Therapeutics and Drug Research Report

Retrieved on: 
Thursday, May 31, 2018
Cancer, RTT, Leukemia, Oncology, Chronic lymphocytic leukemia, CLL, Lymphoid leukemia, Lymphocytic leukemia, Chronic leukemia, B-cell leukemia

ReportsnReports.com adds latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia Pipeline Market Review, H1 2018, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.

Key Points: 
  • ReportsnReports.com adds latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia Pipeline Market Review, H1 2018, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.
  • Another related research report Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018 provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Lymphocytic Leukemia Pipeline Market (ALL) 2018 Analysis, Therapeutics and Drug Research Report

Retrieved on: 
Thursday, May 31, 2018
Cancer, RTT, Leukemia, Oncology, Chronic lymphocytic leukemia, CLL, Lymphoid leukemia, Lymphocytic leukemia, Chronic leukemia, B-cell leukemia

ReportsnReports.com adds latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia Pipeline Market Review, H1 2018, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.

Key Points: 
  • ReportsnReports.com adds latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia Pipeline Market Review, H1 2018, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.
  • Another related research report Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018 provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.